- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Gossamer Bio Inc.
Headquarters: San Diego, CA, United States
Website: http://gossamerbio.com
Year Founded: 2015
Status: Public
Industry Sector: HealthTechnology
CEO: Faheem Hasnain
Number Of Employees: 145
Enterprise Value: $113,009,863
PE Ratio: -4.06
Exchange/Ticker 1: NASDAQ:GOSS
Exchange/Ticker 2: N/A
Latest Market Cap: $240,854,288
BioCentury | May 7, 2024
Deals
Deals report: Novartis strengthens radiotherapy pipeline with pair of deals
Plus: Xyphos-Poseida to develop allogeneic CAR T therapies, Chiesi gains ex-U.S. right to Gossamer’s seralutinib, and more
BioCentury | Dec 6, 2023
Management Tracks
Catalyst hires Michael Kalb as CFO
Plus: Raab to become Amicus chair when Crowley heads to BIO and updates from AC Immune, Gossamer Bio, Chimerix, Versameb, Alzheon, Kling and Avalere
BioCentury | Sep 22, 2023
Politics, Policy & Law
IPO, M&A delays and more: How government shutdown will affect biopharma
FDA will review pending applications, won’t accept new NDAs, BLAs, SEC will not review IPOs
BioCentury | Sep 14, 2023
Management Tracks
Gilead hires a new general manager for Korea
Plus: Character Biosciences hires Gossamer alum Laura Carter as CSO and updates from Hookipa, hC, TCB, LifeSci Partners, Evecxia
BioCentury | Jul 21, 2023
Deals
July 20 Quick Takes: Via its second preclinical deal this week, Sanofi gains Recludix’s oral STAT6 inhibitor
Plus: Idorsia sells Japan, Korea business to Sosei and updates from Gossamer and BioNTech-Biotheus
BioCentury | Apr 4, 2023
Deals
April 4 Quick Takes: Scorpion, Pierre Fabre enter deal for pair of EGFRs
Plus: EUA for InflaRx’s antibody for COVID-19 and updates from Adcendo, Mercy, Mosaic, Freeline and Gossamer
BioCentury | Apr 4, 2023
Finance
Newly launched Cure Ventures taking hands-on approach to company creation
Three co-founders with experience at other firms hope to seed about 20 companies with $350M first fund
BioCentury | Mar 18, 2023
Finance
March 17 Quick Takes: Digital play Pear seeking alternatives
Plus: Gossamer pauses brain-penetrant Btk program, and updates from Pfizer, Astellas, Novartis and more
BioCentury | Jan 12, 2023
Finance
Get used to markets with no nuance, says Blackstone’s Kiran Reddy
2023 will be a year to digest the upheaval of 2022, and the bar for catalysts has been raised: Reddy on The BioCentury Show
BioCentury | Dec 7, 2022
Product Development
Dec. 6 Quick Takes: Gossamer falls on PAH data
Plus: HotSpot, AbbVie in IRF5 collaboration and updates from Leo, MorphoSys-Novartis, Pfizer-Clear Creek
Items per page:
1 - 10 of 58